{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dystrophy%2C+Facioscapulohumeral+Muscular&page=2",
    "query": {
      "condition": "Dystrophy, Facioscapulohumeral Muscular",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dystrophy%2C+Facioscapulohumeral+Muscular&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T09:36:27.824Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02603562",
      "title": "Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy (FSHD)"
      ],
      "interventions": [
        {
          "name": "ATYR1940",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "aTyr Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "16 Years to 25 Years"
      },
      "enrollment_count": 8,
      "start_date": "2016-03-30",
      "completion_date": "2016-12-12",
      "has_results": true,
      "last_update_posted_date": "2023-10-19",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Iowa City, Iowa • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603562"
    },
    {
      "nct_id": "NCT06721299",
      "title": "Clenbuterol to Target DUX4 in FSHD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Muscular Dystrophy, Facioscapulohumeral"
      ],
      "interventions": [
        {
          "name": "Clenbuterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Statland",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-06-25",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 3,
      "location_summary": "Kansas City, Kansas • Rochester, New York • Seattle, Washington",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06721299"
    },
    {
      "nct_id": "NCT02836418",
      "title": "Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy",
        "Limb Girdle Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "ATYR1940",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "aTyr Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "16 Years to 25 Years"
      },
      "enrollment_count": 8,
      "start_date": "2016-07-13",
      "completion_date": "2017-04-18",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 3,
      "location_summary": "Irvine, California • Stanford, California • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02836418"
    },
    {
      "nct_id": "NCT00104078",
      "title": "Study Evaluating MYO-029 in Adult Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Becker Muscular Dystrophy",
        "Facioscapulohumeral Muscular Dystrophy",
        "Limb-Girdle Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "MYO-029",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2005-02",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2007-12-28",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 9,
      "location_summary": "Washington D.C., District of Columbia • Kansas City, Kansas • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104078"
    },
    {
      "nct_id": "NCT00082108",
      "title": "Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myotonic Dystrophy",
        "Facioscapulohumeral Muscular Dystrophy",
        "Muscular Dystrophy",
        "Myotonic Dystrophy Type 1",
        "Myotonic Dystrophy Type 2",
        "Congenital Myotonic Dystrophy",
        "PROMM (Proximal Myotonic Myopathy)",
        "Steinert's Disease",
        "Myotonic Muscular Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3000,
      "start_date": "2000-09",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082108"
    },
    {
      "nct_id": "NCT02927080",
      "title": "Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "ACE-083",
          "type": "DRUG"
        },
        {
          "name": "ACE-083 or placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2016-11",
      "completion_date": "2019-10-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-26",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02927080"
    },
    {
      "nct_id": "NCT03123913",
      "title": "Study of Testosterone and rHGH in FSHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Testosterone Enanthate",
          "type": "DRUG"
        },
        {
          "name": "Somatropin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2017-12-18",
      "completion_date": "2022-03-28",
      "has_results": true,
      "last_update_posted_date": "2023-05-16",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03123913"
    },
    {
      "nct_id": "NCT06096441",
      "title": "FSHD Molecular Characterization",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Facio-Scapulo-Humeral Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-03-05",
      "completion_date": "2025-09-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06096441"
    },
    {
      "nct_id": "NCT02766985",
      "title": "Rasch-analysis of Clinical Severity in FSHD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2016-03",
      "completion_date": "2017-04-18",
      "has_results": false,
      "last_update_posted_date": "2018-04-12",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02766985"
    },
    {
      "nct_id": "NCT02579239",
      "title": "Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Limb-Girdle Muscular Dystrophies",
        "Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "ATYR1940",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "aTyr Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-11-30",
      "completion_date": "2016-10-05",
      "has_results": true,
      "last_update_posted_date": "2023-10-19",
      "last_synced_at": "2026-06-10T09:36:27.824Z",
      "location_count": 3,
      "location_summary": "Irvine, California • Baltimore, Maryland • Columbus, Ohio",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579239"
    }
  ]
}